Viral Vector-Mediated Antisense Therapy for Genetic Diseases

Viral Vector-Mediated Antisense Therapy for Genetic Diseases

RNA plays complex roles in normal health and disease and is becoming an important target for therapeutic intervention; accordingly, therapeutic strategies that modulate RNA function have gained great interest over the past decade. Antisense oligonucleotides (AOs) are perhaps the most promising strategy to modulate RNA expression through a variety of post binding events such as gene silencing th...

Vector-Borne Viral Diseases

1 Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06512, USA 2Department of Biological Sciences, University of Southern Mississippi, Hattiesburg, MS 39406, USA 3Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China 4 Institute of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soocho...

Antisense antivirals: future oligonucleotides-based therapeutics for viral infectious diseases

Despite the availability of antiviral chemotherapies, human pathogenic viral infections remain a global health problem, causing formidable morbidity and mortality worldwide. Of particular concern are those virus types developing (multi)drug-resistance, eg. herpesviruses, hepatitis C virus (HCV), and human immunodeficiency virus (HIV), that fail almost all the available antiviral drugs in clinic...

Novel Viral Vector Systems for Gene Therapy

Legionella Pneumophila and Dendrimers-Mediated Antisense Therapy

Finding novel and effective antibiotics for treatment of Legionella disease is a challenging field. Treatment with antibiotics usually cures Legionella infection; however, if the resultant disease is not timely recognized and treated properly, it leads to poor prognosis and high case fatality rate. Legionella pneumophila DrrA protein (Defects in Rab1 recruitment protein A)/also known as SidM af...